Long-term outcome of isolated limb perfusion with tumour necrosis factor-α for patients with melanoma in-transit metastases
Jan P. Deroose(Cancer Clinic), Cornelis Verhoef(Erasmus MC Cancer Institute), Alexander M.M. Eggermont(University Medical Center Utrecht), Dirk J. Grünhagen(Erasmus MC), Johannes H. W. de Wilt(Radboud University Nijmegen), A.N. van Geel(Erasmus MC)
Cited by 50
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k
Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
|CA A Cancer Journal for Clinicians|2017|2.3k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.9k